Cuvrior FDA Approval History
Last updated by Judith Stewart, BPharm on Aug 24, 2022.
FDA Approved: Yes (First approved April 28, 2022)
Brand name: Cuvrior
Generic name: trientine tetrahydrochloride
Dosage form: Tablets
Company: Orphalan SA
Treatment for: Wilson's Disease
Cuvrior (trientine tetrahydrochloride) is a copper chelator indicated for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.
- Wilson’s Disease is a rare inherited disorder of copper transport that leads to excess copper accumulation. It primarily affects the liver and brain and can be fatal if left untreated.
- Cuvrior tablets are administered orally two times a day on an empty stomach.
- Warnings and precautions associated with Cuvrior include potential for worsening of clinical symptoms at initiation of therapy, copper deficiency, iron deficiency, and hypersensitivity reactions.
- Common adverse reactions include abdominal pain, change of bowel habits, rash, alopecia, and mood swings.
Development timeline for Cuvrior
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
